Clinical Trial of Trametes Versicolor in Women With Breast Cancer

• Quality of life [ Time Frame: Over 6 Weeks ] [ Designated as safety issue: No ]
  as measured by the Functional Assessment of Cancer Therapy-for Patients With Breast, v4.0, questionnaire. The FACT-B is a 37-item quesionnaire using a 5-point Likert scale that evaluates physical well-being, social/family well-being, emotional well-being, functional well-being and additional concerns of breast cancer patients.
• Fatigue [ Time Frame: Over 6 Weeks ] [ Designated as safety issue: No ]
  as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue, v4.0, questionnaire. The FACIT-Fatigue is a 13 item fatigue scale collected at baseline, weekly and 6 weeks, and at the 3 week follow-up visit.
• Symptom Assessment [ Time Frame: Weekly and at 3 Week Follow-Up ] [ Designated as safety issue: Yes ]
  Toxicity will be assessed by the NCI CTCAE v3.0 (see Adverse Event section). The Symptom Assessment questionnaire is completed weekly during study and once at the 3-week follow-up visit
• NK cell activity [ Time Frame: Over 6 weeks ] [ Designated as safety issue: No ]
  Percent change in NK cell activity associated with coriolus versicolor extract
• comparison of immunologic measures [ Time Frame: Baseline and Post-Treatment ] [ Designated as safety issue: No ]

  Will be performed by collecting peripheral blood at baseline, weeks 2,4,6 and 9 during study.

  Preliminary data that compare baseline and post-treatment immunologic measures including natural killer cell activity, phagocytic index, T regulatory cell assay, T/B/NK cell population subset assays, and cytokine levels.

• Quality of life as measured by the Functional Assessment of Cancer Therapy-for Patients With Breast Cancer v4.0 [ Designated as safety issue: No ]
• Fatigue as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue v4.0 and [ Designated as safety issue: No ]
• Toxicity as assessed by the NCI CTCAE v3.0 and the Symptom Assessment questionnaire completed weekly during study and once at the 3-week follow-up visit [ Designated as safety issue: No ]
• Percent change in NK cell activity associated with coriolus versicolor extract [ Designated as safety issue: No ]
• Gather preliminary data that compare baseline and post-treatment immunologic measures including differential blood counts, natural killer cell activity, phagocytic index, and PBMC production of levels of IFN-γ and TNF-α [ Designated as safety issue: No ]

RATIONALE: Coriolus versicolor mushroom extract may slow the growth of cancer cells and may be an effective treatment for breast cancer.

PURPOSE: This phase I trial is studying the side effects and best dose of coriolus versicolor extract in treating women with stage I, stage II, or stage III breast cancer who have finished radiation therapy.

OBJECTIVES:

Primary

• To determine the maximum tolerated dose of oral coriolus versicolor extract in women with stage I-III, estrogen receptor- and/or progesterone receptor-negative or positive (as of 1/26/2009), infiltrating ductal adenocarcinoma of the breast who have recently completed standard post-surgery radiotherapy.

Secondary

• To determine the feasibility of measuring changes in fatigue and quality of life of patients treated with this drug.
• To characterize the toxicity of this drug in these patients.
• To gather preliminary data that compare baseline and post-treatment immunologic measures, including differential blood counts (i.e., WBC), natural killer cell activity, phagocytic index, regulatory cell assay, T/B/NK cell population subset assays, peripheral blood mononuclear cell production of levels of interferon gamma, and tumor necrosis factor-alpha in these patients.

OUTLINE: Patients receive oral coriolus versicolor extract twice daily for 6 weeks.

Patients undergo quality of life and fatigue assessment at baseline, weekly during study, and at the 3-week follow-up visit.

Blood samples are collected periodically for immunological marker studies. Samples are analyzed for T-regulatory cell, T-and B-lymphocyte, and NK cell activity in peripheral blood mononuclear cells (PBMC), phagocytic index in monocytes and granulocytes, and cytokine secretion and upregulation by flow cytometry, cytotoxicity assays, cytolysis assays, T-regulatory cell assay, or T/B/NK cell population subset assays. Changes in the production of tumor necrosis factor-alpha and interferon-gamma in serum and in supernatants of PBMCs are analyzed via standard enzyme-linked immunosorbent assay.

After completion of study treatment, patients are followed at 3 weeks.

Inclusion Criteria:

• Diagnosis, within the previous 12 months with Stage I-III, infiltrating ductal adenocarcinoma of the breast who have undergone surgery and chemotherapy and are able to begin study treatment within 5 days after the last dose of radiotherapy
• Estrogen and/or progesterone receptor-negative or positive
• Willing to eat consistent diet throughout the study, and avoid dietary sources of mushrooms
• Willing to avoid taking any product containing Trametes versicolor, other immune modulating medicinal mushrooms, or other herbal products believed to have immune modulating effects, during radiotherapy and until completion of the subject's last clinic visit on the study.

• Adequate organ function within 14 days of study enrollment including the following:

  • Adequate bone marrow reserve: White blood cells (WBC) ≥ 2,000/mm³, Platelet count ≥ 100,000/mm³, Hemoglobin ≥ 9 g/dL
  • Hepatic: Bilirubin ≤ 20% times upper limit of normal (ULN), Alkaline phosphatase ≤ 20% times ULN, AST and ALT ≤ 20% times ULN
  • Renal: Creatinine ≤ 20% times ULN
  • Nutritional status: Albumin ≥ 3.0 g/dL
• Negative pregnancy test
• Voluntary written consent before performance of any study-related procedure not part of the normal medical care

Exclusion Criteria:

• Pregnant - Patients with reproductive potential must use an approved non-hormonal contraceptive method if appropriate during and for 4 weeks after the last dose of Trametes versicolor.
• Known allergy to fungi, including mushrooms
• Serious concurrent medical or psychiatric disorder (e.g., active infection or uncontrolled diabetes) that, in the opinion of the investigator, would compromise the safety of the patient or the patient's ability to complete the study
• Receipt of hematopoietic growth factors (e.g., Neupogen™, Epogen™) within the previous 4 weeks
• Unwilling to maintain consistency in type and dose of concurrent complementary and alternative medicine therapies
• Unwilling to discontinue excluded medications and supplements